Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhoi, Peter, Bessette, Louis, Bell, Mary J, Tkaczyk, Cathy, Nantel, Francois, Maslova, Karina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623530/
https://www.ncbi.nlm.nih.gov/pubmed/28928177
http://dx.doi.org/10.1136/bmjopen-2017-015872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623530/
https://www.ncbi.nlm.nih.gov/pubmed/28928177
http://dx.doi.org/10.1136/bmjopen-2017-015872

Ejemplares similares